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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMyears, clinical follow-up or death occurred in 95.5% (968/1014) of patients. The 2-
year rate of TVF was 10.4% (101/972), of which 6.4% (62/972) was considered
related to the study stent. Cardiac death was 1.7% (7/987), with 0.2% considered
related to the study stent. Target vessel-related MI was 1.7% (17/972) (1.5% study
stent-related), and TVR was 8.3% (81/972) (5.7% study stent-related). ARC deﬁnite/
probable ST was 1.0% (10/972), with 0.9% (9/972) considered related to the study
stent. Two-year outcomes for subsets, including small vessels, long lesions, and
diabetes, will be available at the meeting.
Conclusions: At 2 years post-procedure, the thin-strut, platinum chromium, pacli-
taxel-eluting TAXUS Element stent continues to demonstrate good performance and
safety in everyday clinical practice.
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Background: Long term outcomes are imperative to conﬁrm safety of drug-eluting
stents. Only two randomized controlled trials have reported 2-year comparisons of
these stents, and no study has reported the 3-year long term clinical outcomes. This
study was performed to compare the long-term clinical outcomes of Xience V/Promus
everolimus-eluting stents (EES) with Resolute zotarolimus-eluting stents (ZES-R) in
“all-comer” cohorts.
Methods: The EXCELLENT and RESOLUTE-Korea registries prospectively
enrolled 3,056 patients treated with EES and 1,998 with ZES-R, respectively, without
exclusions. Stent-related composite outcomes (target lesion failure) and patients-
related composite events up to 3 years follow-up were compared in crude and pro-
pensity score matched analyses.
Results: Of 5054 patients, 3830 patients (75.8%) had off label indication (2217
treated with EES and 1613 treated with ZES-R). The stent-related outcome (189
[6.2%] vs. 127 [6.4%], p¼0.812) and the patient-related outcome (420 [13.7%] vs.
250 [12.5%], p¼0.581) did not differ between EES and ZES-R respectively at 3 year,
which was corroborated by similar results from the propensity score-matched cohort
(HR 0.92, 95% CI 0.70-1.20, p¼0.523 and 0.85, 95% CI 0.70-1.02, p¼0.081, for stent
and patient related outcomes, respectively) . The rate of deﬁnite or probable stent
thrombosis up to 3 years (22 [0.7%] vs. 10 [0.5%], p¼0.370) was also similar. The
rate of very late deﬁnite or probable stent thrombosis was very low and comparable
between the two stents (3 [0.1%] vs. 1 [0.1%], p¼0.657). In multivariate analysis,
chronic renal failure (adjusted HR 3.615, 95% CI 2.440-5.354, p< 0.001) and off label
indication (adjusted HR 1.782, 95% CI 1.169-2.718, p¼0.007) were the strongest
predictors of target lesion failure at 3-year.
Conclusions: In this robust real world registry with unrestricted use of EES and ZES-R,
both stents showed comparable safety and efﬁcacy at 3-year follow-up. Overall in-
cidences of target lesion failure and deﬁnite stent thrombosis, including very late stent
thrombosis, were low, even in the patients with off label indications, suggesting
excellent long term safety and sustained efﬁcacy of both types of second generation
DES.
TCT-582
Percutaneous Coronary Intervention of Very Small Vessels in the RESOLUTE
Global Clinical Program
Antonio Serra1
1Hospital de Sant Pau y Santa Creu, Barcelona, Spain
Background: Limited clinical data is available in patients who underwent percuta-
neous coronary intervention (PCI) with drug eluting stents in very small vessels
(reference vessel diameter [RVD]  2.25 mm).
Methods: We examined the outcomes of patients who underwent PCI using Reso-
luteTM zotarolimus-eluting stent (R-ZES) in the pooled RESOLUTE program in
vessels with RVD 2.25 mm and compared them to those of patients with RVD
>2.25 but 2.75 mm. The RESOLUTE global clinical program includes: RESO-
LUTE First-in-Human, RESOLUTE All Comers (R-AC), RESOLUTE International,
RESOLUTE US, RESOLUTE Japan, RESOLUTE Japan Small Vessel, RESOLUTEJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteAsia, RESOLUTE China, and Resolute China Registry. Target Lesion Failure (TLF)
was the composite of death from cardiac causes, target vessel myocardial infarction
(TV-MI), and target lesion revascularization (TLR). The incidence of clinical events
was calculated using the Kaplan Meier. Given differences in baseline characteristics,
patients were matched by propensity scores based on 24 baseline variables and
adjusted p-values are provided.
Results: A total of 1203 subjects with RVD 2.25 mm RVD and 2773 subjects with
RVD >2.25 but 2.75 mm were treated with R-ZES. Compared with patients with
RVD >2.25 but 2.75 mm, patients with RVD 2.25 mm had more complex
baseline characteristics including prior PCI (33% vs. 26%, p< 0.001) and history of
hypertension (78% vs. 72%, p< 0.001), respectively. However, there was no signif-
icant difference in TLF, TLR, CD/TV-MI or ARC deﬁnite/probable ST at 3 years
(Table).
Conclusions: No increased risk is associated with the use of R-ZES in very small
vessels (RVD2.25 mm) compared with use in small vessels between 2.25 and 2.75
mm. Low rates of clinical events were observed through long-term follow-up in both
groups. Submitted on behalf of the RESOLUTE Global Clinical ProgramTCT-583
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Background: There is still uncertainty about the durability of the results of drug-
eluting stents (DES) in real-world complex patients. We sought to provide the
longest clinical follow-up data on outcomes of unselected patients treated solely
with DES.
Methods: The DESIRE registry is a prospective, single-center registry encom-
passing all consecutive patients treated solely with DES since May 2002. The
primary goal is the very long-term occurrence of MACE and stent thrombosis
(ST). Patients were clinically followed at 1, 6 and 12 months and then annually. A
multivariate model was built to determine independent predictors of MACE, TLR
and ST.
Results: A total of 5,500 patients were included. The mean age was 64  11 years.
DM was detected in 29.7% and 44.8% presented with acute coronary syndrome. SVG
lesions and STEMI represented 6% and 12% of the cohort, respectively. Follow-up
was obtained in 98.2% of the patients (median 5.6 years). Currently, 79.6% of the
population is free of any MACE. TVR was performed in 5.3% of the patients. Q-wave
MI rate was only 1.7% while total ST rate was 1.9%. The majority of deﬁnite ST cases
occurred between the 1st and 3rd years. Independent predictors of MACE were
treatment of SVG (HR 1,63; 95% CI, 1.22 to 2.18, p¼ 0.001), multivessel disease (HR
1.39; 95% CI, 1.03 to 1.87, p< 0.001), residual stenosis (HR 1.3; 95% CI, 1.1 to 1.5,
p¼ 0.034), DM (HR 1.6; 95% CI, 1.1 to 2.2, p¼ 0.006) and renal insufﬁciency (HR
1.5; 95% CI, 1.34 to 1.81, p¼ 0.004). Independent predictors of ST were PCI for
STEMI (HR 3.5; 95% CI, 1.3 to 9.4, p¼ 0.013), stent length (HR 1.8; 95% CI, 1.09 to
3.02, p¼0.023), moderate/severe calciﬁcation at lesion site (HR 2.38; 95% CI, 1.34 to
4.23, p¼0.003), and in-stent residual stenosis (HR 1.04; 95% CI, 1.01 to 1.06,
p¼0.003).
Conclusions: In our single center experience, the use of DES was associated with
very long-term safety and effectiveness with acceptable low rates of adverse clinical
events, including ST.nts - Drug-eluting: Registries B169
